Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Lymphoid 2Thoracic 1Sarcoma 1Plasma cell 1Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Lymphoma, B-Cell 1B-Cell Malignancies 1

Interventions

Cyclophosphamide 211Rituximab 193fludarabine 134fludarabine phosphate 91Vincristine 78Cytarabine 66Etoposide 65Doxorubicin 61Dexamethasone 60Lenalidomide 59venetoclax 56ibrutinib 55Prednisone 54Bendamustine Hydrochloride 51obinutuzumab 48Filgrastim 46Bortezomib 46Specimen Handling 42pembrolizumab 39Gemcitabine 39Methotrexate 38Melphalan 38Biopsy 38Peripheral Blood Stem Cell Transplantation 32Magnetic Resonance Spectroscopy 32Azacitidine 31Vorinostat 29Nivolumab 29Calcium Dobesilate 29Clofarabine 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × urelumab × Lymphoid × Clear all
NCT01471210 2017-04-19

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Bristol-Myers Squibb

Phase 1 Completed
124 enrolled
Lymphoid

Lymphoma, B-Cell

NCT01775631 2017-03-31

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Bristol-Myers Squibb

Phase 1 Completed
47 enrolled
Lymphoid

B-Cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡